Comparison of four pharmacological strategies aimed to prevent the lung infammation and paraquat-induced alveolar damage

ABSTRACT: Objective: The aim of this study was to compare in vivo efect of fve pharmacological options on infammation and pulmonary fbrosis induced by paraquat. Methods: 54 Wistar SPF rats were used. After 2 h post-intoxication with paraquat ion, groups of 9 animals were ran domly assigned to (1) cyclophosphamide plus dexamethasone (2) low molecular weight heparin (3) unfractionated heparin (4) vitamin C every 24 h, (5) atorvastatin or (6) placebo with intraperitoneal saline. Lung infammation, alveolar injury, hepatocyte damage, hepatic regeneration, acute tubular necrosis and kidney congestion were evaluated. Results: In the control group 100% of animals presented moderate and severe lung infammation, while in the groups with atorvastatin and intratracheal heparin this proportion was lower (55.5%; CI 26.6–81.3%) (p=0.025). A lower degree of moderate or severe hepatic regeneration was evident in the treatment groups with atorvastatin (p=0.009). In this study was demonstrated that statins and heparin might have a protective efect in the paraquat induced destructive phase. More evidence is needed to evaluated of dose–response efects of these drugs before to study in clinical trials

• Autores: Buendía Rodríguez, Jefferson Antonio; Justinico Castro, José Armando; Tapia Vela, Laura Joanna; Sinisterra Espejo, Denis María; Sánchez Villamil, Juana Patricia; Zuluaga Salazar, Andrés Felipe
• Tipo de recurso: Article of investigation
• Fecha de publicación: 2019
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: eng
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/38529
• Acceso en línea: https://hdl.handle.net/10495/38529
• Palabra clave: Antioxidantes - Farmacología; Antioxidants - pharmacology; Ácido Ascórbico - Farmacología; Ascorbic Acid - pharmacology; Atorvastatina; Atorvastatin; Pulmón; Lung; Paraquat; Ciclofosfamida; Cyclophosphamide; Dexametasona; Dexamethasone; Quimioterapia Combinada; Drug Therapy, Combination; Heparina de Bajo-Peso-Molecular; Heparin, Low-Molecular-Weight; Neumonía; Pneumonia; Alveolos Pulmonares; Pulmonary Alveoli; Fibrosis Pulmonar; Pulmonary Fibrosis; Ratas Wistar; Rats, Wistar; Resultado del Tratamiento; Treatment Outcome; https://id.nlm.nih.gov/mesh/D000975; https://id.nlm.nih.gov/mesh/D001205; https://id.nlm.nih.gov/mesh/D000069059; https://id.nlm.nih.gov/mesh/D008168; https://id.nlm.nih.gov/mesh/D010269; https://id.nlm.nih.gov/mesh/D003520; https://id.nlm.nih.gov/mesh/D003907; https://id.nlm.nih.gov/mesh/D004359; https://id.nlm.nih.gov/mesh/D006495; https://id.nlm.nih.gov/mesh/D011014; https://id.nlm.nih.gov/mesh/D011650; https://id.nlm.nih.gov/mesh/D011658; https://id.nlm.nih.gov/mesh/D017208; https://id.nlm.nih.gov/mesh/D016896
• Rights: openAccess
• License: https://creativecommons.org/licenses/by/4.0/